Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Breast 3Plasma cell 2Lymphoid 2Head & Neck 2Gynecologic 2Gastrointestinal 1

Conditions

Multiple Myeloma 336Neoplasms, Plasma Cell 62Recurrence 38Lymphoma, Non-Hodgkin 37Leukemia, Lymphocytic, Chronic, B-Cell 35Lymphoma 31Hodgkin Disease 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Mantle-Cell 27Lymphoma, Large B-Cell, Diffuse 27Immunoglobulin Light-chain Amyloidosis 27Lymphoma, Follicular 26Lymphoma, Large-Cell, Immunoblastic 25Lymphoma, B-Cell, Marginal Zone 25Leukemia, Myeloid, Acute 25Neoplasms 24Burkitt Lymphoma 23Leukemia, Myeloid, Chronic-Phase 22Myeloproliferative Disorders 21Leukemia, Myeloid, Accelerated Phase 21Leukemia 21Blast Crisis 21Primary Myelofibrosis 20Lymphoma, T-Cell, Cutaneous 20Leukemia, Hairy Cell 19Waldenstrom Macroglobulinemia 16Myelodysplastic Syndromes 16Leukemia, Myelomonocytic, Chronic 16Sezary Syndrome 15Mycosis Fungoides 15

Interventions

Thalidomide 1Dexamethasone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Pathologic Complete Response × Plasma cell × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

NCT00378222 2006-09-19

Autologous Transplantation for Multiple Myeloma

University of Bologna

Phase 3 Completed
324 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡